학술논문
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Document Type
Article
Author
Source
In ESMO Open February 2021 6(1)
Subject
Language
ISSN
2059-7029